Structure Therapeutics Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Structure Therapeutics Inc. (GPCR) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $38.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- Structure Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $38.80M, a 133.73% increase from fiscal 2024.
- Structure Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $16.60M, a 30.25% decline from fiscal 2023.
- Structure Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $23.80M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $38.80M 10-K · filed 2026-02-26 |
| 2024-12-31 | $16.60M 10-K · filed 2026-02-26 |
| 2023-12-31 | $23.80M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |